Cargando…

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment

Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low whe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chien, Jeremy, Kuang, Rui, Landen, Charles, Shridhar, Viji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781360/ https://www.ncbi.nlm.nih.gov/pubmed/24069583 http://dx.doi.org/10.3389/fonc.2013.00251

Ejemplares similares

The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics
por: Hammond, Edward, et al.
Publicado: (2014)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer
por: Kumar, Sanjeev, et al.
Publicado: (2019)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Network-based Survival Analysis Reveals Subnetwork Signatures for Predicting Outcomes of Ovarian Cancer Treatment
por: Zhang, Wei, et al.
Publicado: (2013)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Deep learning magnetic resonance imaging predicts platinum sensitivity in patients with epithelial ovarian cancer
por: Lei, Ruilin, et al.
Publicado: (2022)

Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018)

How Autophagy Shapes the Tumor Microenvironment in Ovarian Cancer
por: Ferraresi, Alessandra, et al.
Publicado: (2020)

Driving Immune Responses in the Ovarian Tumor Microenvironment
por: Ning, Franklin, et al.
Publicado: (2021)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer
por: Zheng, Hong, et al.
Publicado: (2021)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
por: Zhang, Depu, et al.
Publicado: (2022)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer
por: Chien, Jeremy, et al.
Publicado: (2018)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs
por: Li, Juan, et al.
Publicado: (2023)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer
por: Yan, Jinbowen, et al.
Publicado: (2023)

Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy
por: Seborova, Karolina, et al.
Publicado: (2022)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
por: Worzfeld, Thomas, et al.
Publicado: (2017)

Characterization of 7-Methylguanosine Identified Biochemical Recurrence and Tumor Immune Microenvironment in Prostate Cancer
por: Xin, Sheng, et al.
Publicado: (2022)

Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan
por: Tahara, Makoto, et al.
Publicado: (2020)

Heterotypic Cellular Interactions in the Ovarian Tumor Microenvironment: Biological Significance and Therapeutic Implications
por: Naora, Honami
Publicado: (2014)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

The Role of the Tumor Stroma in Ovarian Cancer
por: Davidson, Ben, et al.
Publicado: (2014)

Prediction of Biochemical Recurrence-Free Survival of Prostate Cancer Patients Leveraging Multiple Gene Expression Profiles in Tumor Microenvironment
por: Zhou, Rui, et al.
Publicado: (2021)

Perplexing Role of P-Glycoprotein in Tumor Microenvironment
por: Robinson, Kianna, et al.
Publicado: (2020)

Role of hypoxia in the tumor microenvironment and targeted therapy
por: Chen, Gaoqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5jlu5qq5f187na3tq343di791b